Concepedia

Publication | Open Access

Expanding Nilotinib Access in Clinical Trials (ENACT)

DOIFull Paper Access

68

Citations

7

References

2011

Year

Franck E. Nicolini, Anna Turkina, Zhixiang Shen, Neil J. Gallagher, Saengsuree Jootar, Bayard L. Powell, Cármino Antônio De Souza, Ming Zheng, Tomasz Szczudlo, Philipp le Coutre
Cancer

Abstract

This large study confirms that nilotinib was well tolerated and that grade 3 or 4 AEs occurred infrequently and were manageable through transient dose interruptions.

References

YearCitations

Page 1